There is substantial evidence from experimental studies that serotonin select-reuptake inhibitors (SSRI's) are effective for treating adolescent depression and anxiety. Positive impacts of SSRI's on depression have been found in two recent experimental studies. In one, Emslie, Rush, Weinberg, Kowatch, Hughes, Carmody and Rintelmann (1997) randomly assigned 96 children and youth (ages 7-17) to a fluoxetine (a type of SSRI) or placebo group for an eight-week period. This was a double-blind study. However, the treatment period was preceded by a two-week diagnostic period and a one-week single-blind placebo period. The researchers found that the fluoxetine group responded more positively than the placebo group (56% vs. 33%). However, only 31% of the fluoxetine group and 23% of the placebo group had complete remission of symptoms. Keller et al. (2001) conducted the first large-scale study of effects of a SSRI called paroxetine (known commercially as Paxil) on adolescent depression. Two hundred seventy-five youth from 12 psychiatric centers were randomly assigned to one of three double-blind treatment groups: paroxetine, imipramine (a tricyclic), or placebo. The researchers found that 63% of the paroxetine group had a reduction in depressive symptoms, compared to 50% of the imipramine and 46% of the placebo group.